Correction (DOI:10.1016/j.jaci.2005.08.048);Innate immunity for biodefense: A strategy whose time has come

Journal of Allergy and Clinical Immunology

Volumn 116, Issue 6, 2005, Pages 1334-1342

  Amlie Lefond, Catherine ^a   Paz, David A ^a   Connelly, Mary P ^a   Huffnagle, Gary B ^b   Dunn, Kyle S ^c   Whelan, Noel T ^a   Whelan, Harry T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c NATIONAL DEFENSE UNIVERSITY   (United States)

Author keywords

Biodefense; Immunomodulation; Innate immunity; Toll like receptors

Indexed keywords

ALPHA INTERFERON; AMPLIGEN; ANTIBODY; CEL 1000; CPG 10101; CPG 7909; CRX 527; CYTOKINE RECEPTOR ANTAGONIST; DIPEPTIDE DERIVATIVE; HIGH MOBILITY GROUP BOX 1 ANTIBODY; IMIQUIMOD; IMMUNOMODULATING AGENT; INTERFERON; OLIGODEOXYNUCLEOTIDE DERIVATIVE; ORAGEN; PEGINTERFERON; SCV 07; THYMOSIN ALPHA1; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 3 AGONIST; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR 9 AGONIST; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; AUTOIMMUNE DISEASE; BIOSENSOR; BLOOD SAMPLING; CHRONIC FATIGUE SYNDROME; DENDRITIC CELL; DRUG ACTIVITY; GASTROINTESTINAL TRACT; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HEPATITIS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; LEISHMANIASIS; MOLLUSCUM CONTAGIOSUM; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW; SEPTIC SHOCK; SKIN CANCER; VIRUS ACTIVATION; VIRUS INFECTION; WART VIRUS;

EID: 28444448351     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.02.003     Document Type: Erratum

References (31)

1. C.J. Hackett Innate immune activation as a broad spectrum biodefense strategy: prospects and research challenges J Allergy Clin Immunol 112 2003 686 694
2. J.T. Cox, K.U. Petry, E. Rylander, and M. Roy Using imiquimod for genital warts in female patients J Womens Health (Larchmt) 133 2004 265 271
3. A.U. Theos, R. Cummins, N.B. Silverberg, and A.S. Paller Effectiveness of imiquimod cream 5% for treating childhood molluscum contagiosum in a double-blind, randomized pilot trial Cutis 74 2004 134 138 141-2
4. I. Arevalo, B. Ward, R. Miller, T.C. Meng, E. Nagar, and E. Alvarez Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator Clin Infect Dis 33 2001 1847 1851
5. A. Krug, S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell, and Z.K. Ballas Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells Eur J Immunol 31 2001 2154 2163
6. M. Gursel, D. Verthelyi, and D.M. Klinman CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells Eur J Immunol 32 2002 2617 2622
7. J. Vollmer, R. Weeratna, P. Payette, M. Jurk, C. Schetter, and M. Laucht Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities Eur J Immunol 34 2004 251 262
8. F. Obermeier, N. Dunger, L. Deml, H. Herfarth, J. Scholmerich, and W. Falk CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodium-treated mice Eur J Immunol 32 2002 2084 2092
9. A. Grajkowski, J. Pedras-Vasconcelos, V. Wang, C. Ausin, S. Hess, and D. Verthelyi Thermolytic CpG-containing DNA oligonucleotides as potential immunotherapeutic prodrugs Nucleic Acids Res 33 2005 3550 3560
10. D.M. Klinman Immunotherapeutic uses of CpG oligodeoxynucleotides Nat Rev Immunol 4 2004 249 259
11. D. Verthelyi, M. Gursel, R.T. Kenney, J.D. Lifson, S. Liu, and J. Mican CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection J Immunol 170 2003 4717 4723
12. C.A. Leifer, D. Verthelyi, and D.M. Klinman Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides J Immunother 26 2003 313 319
13. D. Wang, E.R. Kandimalla, D. Yu, J.X. Tang, and S. Agrawal Oral administration of second generation immunomodulatory oligonucleotides induces mucosal Th1 immune responses and adjuvant activity Vaccine 23 2005 2614 2622
14. E.R. Kandimalla, B. Bhagat, Y. Li, D. Yu, D. Wang, and Y.P. Cong Immunomodulatory oligonucleotides containing a cytosine-phosphate-2′- deoxy-7-deazaguanosine motif as potent Toll-like receptor 9 agonists Proc Natl Acad Sci U S A 102 2005 6925 6930
15. A. Billich Thymosin alpha1. SciClone Pharmaceuticals Curr Opin Investig Drugs 3 2002 698 707
16. L. Romani, F. Bistoni, R. Gaziano, S. Bozza, C. Montagnoli, and K. Perruccio Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling Blood 103 2004 4232 4239
17. Q. Sha, A.Q. Truong-Tran, J.R. Plitt, L.A. Beck, and R.P. Schleimer Activation of airway epithelial cells by toll-like receptor agonists Am J Respir Cell Mol Biol 31 2004 358 364
18. 12U)] markedly protects mice against coxsackie B3 virus-induced myocarditis Antimicrob Agents Chemother 48 2004 267 274
19. C.W. Cluff, J.R. Baldridge, A.G. Stöver, J.T. Evans, D.A. Johnson, and M.J. Lacy Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge Infect Immun 73 2005 3044 3052
20. A.G. Stöver, J. Da Silva Correia, J.T. Evans, C.W. Cluff, M.W. Elliott, and E.W. Jeffery Structure-activity relationship of synthetic toll-like receptor 4 agonists J Biol Chem 279 2004 4440 4449
21. B. Hahm, M.J. Trifilo, E.I. Zuniga, and M.B. Oldstone Viruses evade the immune system through type I interferon-mediated STAT2-dependent, but STAT1-independent, signaling Immunity 22 2005 247 257
22. T. Nishiwaki, H. Yoneyama, Y. Eishi, N. Matsuo, K. Tatsumi, and H. Kimura Indigenous pulmonary propionibacterium acnes primes the host in the development of sarcoid-like pulmonary granulomatosis in mice Am J Pathol 165 2004 631 639
23. S.J. Matthews, and C. McCoy Peginterferon alfa-2a: a review of approved and investigational uses Clin Ther 26 2004 991 1025
24. G. Liu, Q. Zhai, D.J. Schaffner, A. Wu, A. Yohannes, and T.M. Robinson Prevention of lethal respiratory vaccinia infections in mice with interferon-alpha and interferon-gamma FEMS Immunol Med Microbiol 40 2004 201 206
25. S.J. Sperber, and F.G. Hayden Antiviral chemotherapy and prophylaxis of viral respiratory disease Clin Lab Med 7 1987 869 896
26. F.G. Hayden Clinical applications of antiviral agents for chemophrophylaxis and therapy respiratory viral infections Antiviral Res suppl 1 1985 229 239
27. Y. Charoenvit, G.T. Brice, D. Bacon, V. Majam, J. Williams, and E. Abot A small peptide (CEL-1000) derived from the beta-chain of the human major histocompatibility complex class II molecule induces complete protection against malaria in an antigen-independent manner Antimicrob Agents Chemother 48 2004 2455 2463
28. A. Simbirtsev, A. Kolobov, N. Zabolotnych, N. Pigareva, V. Konusova, and A. Kotov Biological activity of peptide SCV-07 against murine tuberculosis Russ J Immunol 8 2003 11 22
29. H. Erlandsson, and U. Andersson The nuclear protein HMGB1 as a proinflammatory mediator Eur J Immunol 34 2004 103 112
30. H. Yang, M. Ochani, J. Li, X. Quiang, M. Tanovic, and H.E. Harris Reversing established sepsis with antagonists of endogenous high-mobility group box 1 Proc Natl Acad Sci U S A 101 2004 296 301
31. J.I. Webster, and E.M. Sternberg Role of the hypothalamic-pituitary- adrenal axis, glucocorticoids and glucocorticoid receptors in toxic sequelae of exposure to bacterial and viral products J Endocrinol 181 2004 207 221